Compare KRT & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | FBRX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 487.2M |
| IPO Year | 2019 | 2017 |
| Metric | KRT | FBRX |
|---|---|---|
| Price | $30.18 | $34.10 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $26.50 | ★ $67.00 |
| AVG Volume (30 Days) | 75.2K | ★ 405.4K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | 4.70 | ★ 61.30 |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $467,743,000.00 | $36,000.00 |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | $19.36 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $20.61 | $4.91 |
| 52 Week High | $32.68 | $35.80 |
| Indicator | KRT | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 64.26 |
| Support Level | $21.64 | $26.67 |
| Resistance Level | N/A | $35.71 |
| Average True Range (ATR) | 0.83 | 3.25 |
| MACD | 0.01 | 0.77 |
| Stochastic Oscillator | 81.33 | 88.32 |
Karat Packaging Inc is engaged in the manufacturing and distribution of disposable products used in restaurants and food service settings. The company operates and evaluates its business as a single reportable segment which encompasses the manufacturing and distribution of a diverse range of single-use food and beverage service products made from materials such as plastic, paper, biopolymer-based, and other compostable forms. The company offers products for the foodservice industry, including food packaging, containers, tableware, cups, lids, cutlery, and straws. These products are available in plastic, paper, biopolymer-based and other compostable forms. Its product line includes a variety of brands such as Tea Zone, Karat, Karat Earth, and Total Clean.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.